Platelet serotonergic parameters and clinical symptoms of psychosis in patients with episodic progressive schizophrenia

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 107, Issue 4, 2007, Pages 17-24

  Brusov, O S ^a   Factor, M I ^a   Zlobina, G P ^a   Dupin, A M ^a   Katasonov, A B ^a   Dmitriev, A D ^a   Pavlova, E V ^a   Beniashvili, A C ^a   Morozova, M A ^a  

^a NONE

Author keywords

Markers; Platelet serotonin; Prevalence; Psychosis; Schizophrenia; Serotonin transporter; Sex dimorphism

Indexed keywords

EID: 34249718251     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Russian source
2. Russian source
3. Russian source
4. Advokat C. Differential effects of clozapine versus other amipsychotics on clinical outcome and dopamine release in the brain. Essent Psychopharmacol 2005; 6: 2: 73-90.
5. Arora A.C., Meltzer H. Y. Serotonin uptake by bood platelets of schizophrenic patients. Psychiat Res 1982; 6: 327-333.
6. Borcsiczky D., Tekes K., Tarcall J. et al. Platelet rich plasma serotonin content in patients suffering fro different psychiatric disorders. Acta Physiol Hung 1996; 84: 403-404.
7. Brier A., Berg P.H. The psychosis of schizophrenia: prevalence, response to atypical antidepressants. and prediction of outcome. Biol Psychiat 1999; 46: 362-364.
8. Citrome L., Bilder R.M., Volavka J. Managing treatment-resistant schizophrenia: evidence from randomized clinical trials. J Psychiat Pract 2002; 8: 4: 205-215..
9. Daw L., Blakely R.D., Munn J.L. et al. Evidence that adenosine receptor-linked protein kinase G and p38 MARK acutely regulate the serotonin transporter in vivo. Program No10. Abstract Viewer. Nashville, TN: American College of Neuropsychopharmacology 2004; 34.
10. Dmitriev A.D., Pavlova E. V., Factor M.I. et al. Analysis of serotonin transporter in human platelets by immunoblotting using site-specific antibodies. Biochemistry (Moscow) 2004; 69: 629-641.
11. Dmitriev A.D., Factor M.I., Segal O.L. et al. Western blot analysis of human and rat serotonin transporter in platelets and brain using site-specific antibodies: evidence that transporter undergoes endoproteolytic cleavage. Clin Chim Acta 2005; 356: 76-94.
12. Frattini P., Cucchi M.L., Santagostino G. et al. A sensitive fluorimetric method for determination of platelet-bound and plasma free serotonin. Clin Chim Acta 1979; 92: 353-360.
13. Guy W. ECDEU Assessment Manual for Psychopharmacology. Bethesda, MD: US, Department of Health, Education, and Welfare. 1976.
14. Hassan S., Dinakar M.D., Robert N. et al. Efficacy of Olanzapine and Risperidone for Treatment-Refractory Schizophrenia Among Long-Stay State Hospital Patients. Psychiat Serv 2002; 53: 755-757.
15. Heckers S. Neural models of schizophrenia. Dialogues in Clinical Neuroscience. 2000; 2: 267-280.
16. Iqbal N., van Praag H.M. The role of serotonin in schizophrenia. Eur Neuropsychopharmacol 1995; 5: Suppl 5: 11-23.
17. Jackman H., Luchins D., Meltzer H. Y. Platelet serotonin levels in schizophrenia: relationship to race and psychopathology. Biol Psychiat 1983; 18: 887-902.
18. Jakovljevic M., Muck-Seler D., Pivac N. et al. Seasonal influence on platelet 5-HT levels in patients with recurrent major depression and schizophrenia. Biol Psychiat 1997; 41: 1028-1034.
19. Jakovljevic M., Muck-Seler D., Pivac N. et al. Platelet 5-HT and plasma cortisol concentrations after dexamethasone suppression test in patients with different time course of schizophrenia. Neuropsychobiology 1998; 37: 142-145.
20. Kay S.P., Opler L.A., Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda. NY: Multi-Health Systems Inc 1986.
21. Lancon C., Auquier P., Reiner G. et al. Relationships between depression and psychotic symptoms of schizophrenia during an acute episode and stable period. Schizophr Res 2001; 47: 135-140.
22. Laurielo J., Bustillo J. Medication treatment for schizophrenia: translation research findings into better outcomes. J Psychiat Pract 2001; 7: 260-265.
23. Meszaros Z., Borcsiczky D., Mate M. et al. MAO inhibitory side effects of neuroleptics and platelet serotonin content in schizophrenic patients. J Neural Transm Suppl 1998; 52: 79-85.
24. Muck-Seler D., Jakovljevic M., Deanovic Z. Time course of schizophrenia and platelet 5-HT level. Biol Psychiat 1988; 23: 243-251.
25. Muck-Seler D., Pivac N., Jakovljevic M. Sex differences, season of birth and platelet 5-HT levels in schizophrenic patients. J Neural Transm 1999; 106: 337-347.
26. Muck-Seler D., Pivac N., Jakovljevic M., Brzovic Z. Platelet serotonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients. Biol Psychiat 1999; 45: 1433-1439.
27. Pivac N., Muck-Seler D., Jakovljevic M. Platelet 5-HT levels and hypothalamic-pituitary-adrenal axis activity in schizophrenic patients with positive and negative symptoms. Neuropsychobiology 1997; 36: 19-21.
28. Remington G., Saha A., Chong S.A. et al. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2006; 20: 171.
29. Stahl S.M., Woo D.J., Mefford I. N. et al. Hyperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders. Am J Psychiat 1983; 140: 26-30.
30. Tangen O., Herman H.J., Marfey P. Gel filtration. A new technique for separation of blood platelets from plasma. Thrombos Diathes Haemorrh 1971; 25: 268-278.
31. Van der Heijden P.M., Tuinier S.,Fekkes D. et al. Atypical antipsychotics and the relevance of glutamate and serotonin. Eur Neuropsychopharmacol 2004; 14: 29-65.
32. Yao J.K., van Kammen D.P., Gurklis J. et al. Platelet aggregation and dense granule secretion in schizophrenia. Psychiat Res 1994; 54: 13-24.
33. Yao J.K., van Kammen D.P., Moss H.B., Sokulski D.E. Decreased serotonergic responsivity in platelets of drug-free patients with schizophrenia. Psychiat Res 1996; 63: 123-132.
34. Zhu C.B., Hewlett W.A., Feoktistov I. et al. Adenosine receptor, protein kinase G, and p38 mitogen-activated protein kinasc-dependent upregulation of serotonin transporters involves both transporter trafficking and activation. Mol Pharmacol 2004; 65: 1462-1474.